Business
Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Rxilient Medical Pte. Ltd. ("Rxilient"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine currently indicated for the treatment of inflammation and pain following ocular surgery in key ASEAN regions, including Indonesia, Philippines, Singapore, and Thailand. R
About this update from Formosa Laboratories, Inc.
[{"type":"text","content":"TAIPEI, Dec. 3, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Rxilient Medical Pte. Ltd. ("Rxilient"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine currently indicated for the treatment of inflammation and pain following ocular surgery in key ASEAN regions, including Indonesia, Philippines, Singapore, and Thailand. Rxilient, with growing presence in Southeast Asia regions and Middle East and North Africa regions, strives to be the partner-of-choice for innovative ophthalmic products. The licensing agreement includes upfront, regulatory milestones, and sales milestones.","length":839,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Formosa Pharmaceuticals Inc.,)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Formosa Pharmaceuticals Inc.,)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/df2f2b8e7dc998aaa222bb4fda4ccb64"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EZtI6hNhHY8Dmsi4mqUzcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df2f2b8e7dc998aaa222bb4fda4ccb64","width":400,"height":121}},"href":"https://mma.prnewswire.com/media/2002027/1_1_1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation, approved by the US FDA in 2024, enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a US survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. The licensing territory is estimated to have over 1 million ocular surgeries annually with anticipated YOY growth.","length":720,"tagName":"p"},{"type":"text","content":""We are pleased to establish this ...